Celgene posted an "uneventful quarter" on Thursday, putting the biotech leader one step closer to its merger with Bristol-Myers Squibb. Shares dipped early Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,